Watch this short video to see CRIO’s system in action. You’ll see how easy and intuitive our system is.
Whether your visits are done in-clinic, at home, or virtually, your sites are responsible for collecting source data, and you are responsible for providing oversight and source data verification. With CRIO, you can see your sites’ source data, associated PDFs such as consents or labs, regulatory files, and delegation log, all in one place, online. You can generate queries that your sites can respond to. And everything comes with a 21 CFR 11-compliant audit trail, so you know who recorded what data point, when they did it, and why they made changes. Your CRAs only have to travel to the site for IP reconciliation and face-to-face training and dialogue.
Reimburse your sites for the use of our system. We recommend a reimbursement policy of $2,000 for eSource and $1,000 for eRegulatory. If you want assistance locating eSource-ready sites, please email us here: email@example.com
Design of eSource template; includes protocol amendments
Activation and training of new sites (non-CRIO clients)
Use of eSource and eRegulatory during trial, with customer support
15 to 25 years post-closeout electronic archiving of all records
From start to finish, we can design and deploy the templates within 2-4 weeks
A simple flat low price; $2000 per site if over 20 sites sign up
We have a full-service offering where we can build the study template, as well as activate and train all sites on your trial, including CRIO-naive sites.
According to a third party survey of CRAs who have used the CRIO system, CRAs favor CRIO over paper by up to 3:1 margins
“If planned on-site monitoring visits are no longer possible, sponsors should consider optimizing use of central and remote monitoring programs to maintain oversight of clinical trials.”
“91% of sites would utilize an eSource system furnished by the sponsor to facilitate remote monitoring”
“Nearly two-thirds of sites prohibit on-site monitoring.”
“I am writing this email to express my gratitude towards the incredible capability of CRIO and the ability for our Cancer Trials Unit to actually continue to operate and provide data remotely during a pandemic such as this.“
- Lewis Edwards, Linear Clinical Research (Perth, Australia)